Why the study?
Current AAV production strategies face challenges of low yield and poor quality, limiting their ability to meet clinical demands for gene therapy.
A novel Cap-Rep dual control system significantly enhances AAV manufacturing efficiency and yield in HEK293 cells, potentially reducing production costs for gene therapy vectors.
No takes yet. Share an insight, caveat, or question.
May lower AAV manufacturing costs; leaves open scalability for clinical gene therapy production.
Ren et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: